We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Adsorption Procedure Enhances Efficiency of Drug Transport

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: Combining a nanocarrier with antibodies under acidic conditions results in the antibodies attaching to the drug carrier in a stable way. This makes it possible for nanocarriers to target diseased tissue (Photo courtesy of Stefan Schuhmacher).
Image: Combining a nanocarrier with antibodies under acidic conditions results in the antibodies attaching to the drug carrier in a stable way. This makes it possible for nanocarriers to target diseased tissue (Photo courtesy of Stefan Schuhmacher).
A simple adsorption procedure enhances the efficiency of nanocarrier transport of toxic drugs to tumors.

To promote drug delivery to exact sites and cell types, the surface of nanocarriers is functionalized with targeting antibodies or ligands, typically coupled by covalent chemistry. Once the nanocarrier is exposed to biological fluid such as plasma, however, its surface is inevitably covered with various biomolecules forming a protein corona, which masks the targeting ability of the nanoparticle.

To get around the protein-masking problem, investigators at Johannes Gutenberg University Mainz (Germany) developed a pre-adsorption process to attach targeting antibodies to the surface of the nanocarrier.

The investigators reported in the June 18, 2018, online edition of the journal Nature Nanotechnology that pre-adsorbed antibodies remained functional and were not completely exchanged or covered by the biomolecular corona, whereas coupled antibodies were more affected by this shielding.

"Up to now, we have always had to use elaborate chemical methods to bind these antibodies to nanocapsules," said senior author Dr. Volker Mailänder, head of the nanocarriers for medical applications group at the Johannes Gutenberg University Mainz. "We have now been able to show that all that you need to do is to combine antibodies and nanocapsules together in an acidified solution."

Related Links:
Johannes Gutenberg University Mainz

Gold Supplier
Liquid Handling Workstation
Seegene STARlet IVD
New
Gold Supplier
Nucleic Acid Extraction System
SMPE-960
New
Molecular Diagnostic System
iPonatic
New
SARS-CoV-2 Antibody ELISA Kit
SARS-CoV-2 N-Protein Salivary IgG ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.